“Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. 2023. SKIN The Journal of Cutaneous Medicine 7 (6): s241. https://doi.org/10.25251/skin.7.supp.241.